semaglutide compounding lawsuit news Novo's GLP-1 Patent Suit Against Hims Takes Aim at Despite FDA ruling, compounded GLP-1s

Bloodwork Before Starting Getting baseline bloodwork done before starting Retatrutide is a genuinely worthwhile step, not a formality

29 The failure of this strategy serves as a cautionary tale for other firms contemplating aggressive, non-traditional defensive tactics, highlighting the legal and reputational risks involved

The results of these trials have consistently demonstrated the cardiovascular benefits associated with GLP-1 receptor agonists including reductions in major adverse cardiovascular events

To meet demand, both Lilly and Novo look to expand supply capacity of their GLP-1 portfolios

At the highest tested dose of 12mg weekly, Retatrutide produced an average weight loss of 24.2% over 48 weeks